AAAAAA

   
Results: 1-19 |
Results: 19
Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia
Authors: Makris, M Baglin, T Dusheiko, G Giangrande, PLF Lee, CA Ludlam, CA Preston, FE Watson, HG Wilde, JT Winter, M
Citation: M. Makris et al., Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia, HAEMOPHILIA, 7(4), 2001, pp. 339-345
Protecting travellers from hepatitis A - Vaccine should be used for almostevery occasion when prevention is required
Authors: Webster, G Barnes, E Dusheiko, G Franklin, I
Citation: G. Webster et al., Protecting travellers from hepatitis A - Vaccine should be used for almostevery occasion when prevention is required, BR MED J, 322(7296), 2001, pp. 1194-1195
The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis
Authors: Papatheodoridis, GV Davies, S Dhillon, AP Teixeira, R Goulis, J Davidson, B Rolles, K Dusheiko, G Burroughs, AK
Citation: Gv. Papatheodoridis et al., The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis, TRANSPLANT, 72(3), 2001, pp. 412-418
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography
Authors: Karadimitris, A Gadola, S Altamirano, M Brown, D Woolfson, A Klenerman, P Chen, JL Koezuka, Y Roberts, IAG Price, DA Dusheiko, G Milstein, C Fersht, A Luzzatto, L Cerundolo, V
Citation: A. Karadimitris et al., Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography, P NAS US, 98(6), 2001, pp. 3294-3298
HCV genotypes - role in pathogenesis of disease and response to therapy
Authors: Webster, G Barnes, E Brown, D Dusheiko, G
Citation: G. Webster et al., HCV genotypes - role in pathogenesis of disease and response to therapy, BEST PR RES, 14(2), 2000, pp. 229-240
Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers
Authors: Lechner, F Sullivan, J Spiegel, H Nixon, DF Ferrari, B Davis, A Borkowsky, B Pollack, H Barnes, E Dusheiko, G Klenerman, P
Citation: F. Lechner et al., Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers, PHI T ROY B, 355(1400), 2000, pp. 1085-1092
Organ transplantation and discrimination - Patients with hepatitis B should not be given low priority
Authors: Webster, G Barnes, E Burroughs, A Dusheiko, G
Citation: G. Webster et al., Organ transplantation and discrimination - Patients with hepatitis B should not be given low priority, BR MED J, 320(7249), 2000, pp. 1600-1601
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up
Authors: Mutimer, D Dusheiko, G Barrett, C Grellier, L Ahmed, M Anschuetz, G Burroughs, A Hubscher, S Dhillon, AP Rolles, K Elias, E
Citation: D. Mutimer et al., Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up, TRANSPLANT, 70(5), 2000, pp. 809-815
The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985
Authors: Yee, TT Griffioen, A Sabin, CA Dusheiko, G Lee, CA
Citation: Tt. Yee et al., The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985, GUT, 47(6), 2000, pp. 845-851
The science, economics, and effectiveness of combination therapy for hepatitis C
Authors: Dusheiko, G Barnes, E Webster, G Whalley, S
Citation: G. Dusheiko et al., The science, economics, and effectiveness of combination therapy for hepatitis C, GUT, 47(2), 2000, pp. 159-161
Global surveillance and control of hepatitis C
Authors: Lavanchy, D Purcell, R Hollinger, FB Howard, C Alberti, A Kew, M Dusheiko, G Alter, M Ayoola, E Beutels, P Bloomer, R Ferret, B Decker, R Esteban, R Fay, O Fields, H Fuller, EC Grob, P Houghton, M Leung, N Locarnini, SA Margolis, H Meheus, A Miyamura, T Mohamed, MK Tandon, B Thomas, D Head, HT Toukan, AU Van Damme, P Zanetti, A Arthur, R Couper, M D'Amelio, R Emmanuel, JC Esteves, K Gavinio, P Griffiths, E Hallaj, Z Heuck, CC Heymann, DL Holck, SE Kane, M Martinez, LJ Meslin, F Mochny, IS Ndikuyeze, A Padilla, AM Rodier, GRM Roure, C Savage, F Vercauteren, G
Citation: D. Lavanchy et al., Global surveillance and control of hepatitis C, J VIRAL HEP, 6(1), 1999, pp. 35-47
Hepatitis C Lookback Programme: a single hospital experience
Authors: Pawson, R Rajan, S Hazlehurst, G Dusheiko, G Miller, R Hewitt, P Mehta, A
Citation: R. Pawson et al., Hepatitis C Lookback Programme: a single hospital experience, TRANSFUS M, 9(3), 1999, pp. 189-193
EASL International Consensus Conference on Hepatitis C - Paris, 26-27 February 1999 - Consensus statement (Reprinted from Journal of Hematology, vol 30, pg 956-961, 1999)
Authors: Marcellin, P Alberti, A Dusheiko, G Esteban, R Manns, M Shouval, D Weiland, O Williams, R Benhamou, JP Rodes, J Alter, H Bismuth, H Desmet, V Guardia, J Heathcote, J Lok, A Maddrey, WC Zum Buschenfelde, KHM Pagliaro, L Paumgartner, G Sherlock, S Abrignani, S Alberti, A Alter, M Bonino, F Bortolotti, F Brechot, C de Moura, MC Carreno, V Colombo, M Craxi, A Davis, G De Francesco, R Degos, F Di Bisceglie, A Dienes, H Dusheiko, G Esteban, J Esteban, R Farci, P Ferrari, C Foster, G Hadziyannis, S Hoofnagle, J Koff, R Lavanchy, D Lindsay, K Lunel, F Manns, M Marcellin, P Mondelli, M Nalpas, B Naoumov, N Pawlotsky, JM Pol, S Pontisso, P Poynard, T Prieto, J Rizzetto, M Roggendorf, M Moreno, MR Samuel, D Sanchez-Tapias, J Schalm, S Shouval, D Simmonds, P Soriano, V Tassopoulos, N Thomas, H Trepo, C Van der Poel, CL Vogel, W Weiland, O Wejstal, R Williams, R Wright, T Zanetti, A Zarski, JP Zeuzem, S Zoulim, F
Citation: P. Marcellin et al., EASL International Consensus Conference on Hepatitis C - Paris, 26-27 February 1999 - Consensus statement (Reprinted from Journal of Hematology, vol 30, pg 956-961, 1999), J HEPATOL, 31, 1999, pp. 3-8
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin
Authors: Barnes, E Webster, G Jacobs, R Dusheiko, G
Citation: E. Barnes et al., Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin, J HEPATOL, 31, 1999, pp. 244-249
A pill a day, or two, for hepatitis B? (vol 353, pg 32, 1999)
Authors: Dusheiko, G
Citation: G. Dusheiko, A pill a day, or two, for hepatitis B? (vol 353, pg 32, 1999), LANCET, 353(9165), 1999, pp. 1714-1714
A pill a day, or two, for hepatitis B?
Authors: Dusheiko, G
Citation: G. Dusheiko, A pill a day, or two, for hepatitis B?, LANCET, 353(9158), 1999, pp. 1032-1033
Lamivudine therapy for hepatitis B infection
Authors: Dusheiko, G
Citation: G. Dusheiko, Lamivudine therapy for hepatitis B infection, SC J GASTR, 34, 1999, pp. 76-81
Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens
Authors: Papatheodoridis, GV Barton, SGRG Andrew, D Clewley, G Davies, S Dhillon, AP Dusheiko, G Davidson, B Rolles, K Burroughs, AK
Citation: Gv. Papatheodoridis et al., Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens, GUT, 45(3), 1999, pp. 427-434
Effect of coinfection with hepatitis G virus on HIV disease progression inhemophilic men
Authors: Sabin, CA Devereux, H Kinson, Z Griffioen, A Brown, D Dusheiko, G Lee, CA
Citation: Ca. Sabin et al., Effect of coinfection with hepatitis G virus on HIV disease progression inhemophilic men, J ACQ IMM D, 19(5), 1998, pp. 546-547
Risultati: 1-19 |